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Background: HER2 status assessment is a prerequisite for the establishment of an appropriate treatment strategy in
gastric cancer. Gastric cancers are very heterogeneous and separate evaluations of gene amplification and protein
expression lead to uncertainties in localizing distinct clones and are time consuming. This study evaluates the
equivalence of the novel method combining both gene and protein platforms on one slide.
Methods: Immunohistochemistry (IHC) and HER2 dual-colour silver in situ hybridization (SISH) as single methods
(IHC/SISH) and gene-protein platform combining both methods on one slide (gene/protein) were performed in
randomly collected 100 cases of gastric adenocarcinoma. Results of IHC/SISH were compared with gene/protein
staining.
Results: 96 of 100 samples were assessable. In the gene/protein staining, pathologists were able to assess gene
amplification and consequent protein expression at the single cell level. In comparison trials, gene amplification
was observed in 14.6% by both, conventional SISH and gene/protein platform (agreement 100%; Kappa-coefficient
κ = 1.0). Protein expression scores by IHC were 70.8% (0), 10.4% (1+), 9.4% (2+), and 9.4% (3+). Protein expression
by gene/protein method were: 70.8% (0), 11.5% (1+), 7.3% (2+) and 10.4% (3+) of patients. There were complete
concordances in IHC assessment of cases with score 0 (100.0%; κ = 1). High concordances are shown in score 1+
(98.96%; κ = 0.947) and 3+ (96.88%; κ = 0.825) cases and good concordances in 2+ cases (95.83%; κ = 0.728).
Conclusions: This novel combined platform has the advantage of being able to evaluate both gene and the
protein status in the same cancer cell and may be of particular interest for research and patient’s care.
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The HER2 oncogene (also referred to as HER2/neu or
ERBB-2) on chromosome 17q21, encodes a 185-kD trans-
membrane tyrosine kinase receptor that belongs to the
epidermal growth factor receptor (EGFR) family com-
prised of EGFR/HER1, HER2, HER3, and HER4. HER2
activation plays a central role in cell proliferation and sur-
vival, largely mediated through the RAS–MAPK pathway.
It also inhibits cell death through the phosphatidylinositol
3'-kinase–AKT–mammalian target of rapamycin (mTOR)
pathway. HER2 overexpression has been reported in a
variety of solid tumors [1-7]. Gene amplifications are rare
in other diseases and anti-HER2 therapy is currently vali-
dated only in breast and gastric cancers.
Based on the results of the ToGA trial [8], trastuzumab
was approved for metastatic adenocarcinoma of the sto-
mach and gastroesophageal junction in combination ther-
apy in the US and Europe. Requirement is proof of HER2
overexpression. In Europe, this is defined by an IHC
3+ result or an IHC 2+ and positive FISH or SISH result
(ratio ≥ 2.0). IHC was considered the primary method be-
cause IHC negative or weekly positive (1+) patients did
not benefit from trastuzumab in the ToGA trial, although
they were ISH positive. In the literature, however, there is
considerable variation in the immunohistochemical posi-
tivity determined. Here, the percentage of HER2 positive
advanced gastric adenocarcinomas varies from study to
study, from 5% to 30% [9], most likely due to different
analysis protocols and interpretation criteria.
Prospective substudies from two of the adjuvant ran-
domized trials of trastuzumab versus nil in breast cancer
demonstrated that approximately 20% of HER2 assays
performed at on-site institutions (at the primary treat-
ment site’s pathology department) were incorrect when
the same specimen was re-evaluated in a high volume,
central laboratory [10,11].
Unlike breast cancer, the histopathology of gastric can-
cer in terms of HER2 is considered to be more heteroge-
neous and focal overexpression of gene amplification is
frequently observed [12]. Therefore, difficulties in deter-
mining the HER2 status are expected to be more pro-
nounced than in breast cancer. Overall, taken these results
into account, more reliable, reproducible and time sparing
methods for assessing the HER2 status in gastric cancer
are needed. Only few published studies combining IHC
and in situ hybridization methods (but not SISH) on one
slide have been conducted [13-16]. Theses studies utilized
standard IHC and chromogenic or fluorescence in situ
hybridization (CISH or FISH) as single methods and
compared them with a simultaneous analysis (combined
on one slide) and found good concordance with results of
single staining. To the best of our knowledge, however,
there are no studies that directly compare results of
both immunohistochemistry (IHC) and silver in situhybridization (SISH) when each is used separately with
the results of using them in combination on a single
section in gastric carcinomas.
In the present study, the HER2 protein expression and
gene amplification status of 100 gastric adenocarcinomas
and carcinomas of the esophagogastric junction were
examined by conventional IHC and ISH single methods
(IHC/SISH) and in parallel by the novel method com-
bining both methods (gene/protein). The aim of this
study was to evaluate the equivalence of the new gene-
protein platform in comparison to the single staining
methods.
Methods
Patients and tissue samples
Formalin-fixed paraffin-embedded (FFPE) tumor samples
from 100 patients with gastric or gastroesophageal junc-
tion adenocarcinoma were selected from a tissue archive
of samples at the Institute of Pathology at Krankenhaus
Nordwest. The project was performed with the permission
of the responsible ethic committee. For each case, four
different staining methods were used according to the
manufacturer´s FDA-approved procedures: hematoxylin
and eosin (H&E) to assess the sample adequacy and to
confirm the histological subtype, immunohistochemistry
(IHC) to evaluate the HER2 protein expression, silver in
situ hybridization (SISH) to evaluate the gene amplifica-
tion and the novel gene-protein platform which combines
IHC and SISH on one slide.
Immunohistochemistry
IHC was performed with the FDA-approved Ventana
PATHWAY rabbit monoclonal antibody 4B5 clone and
with the ultraVIEW DAB Detection Kit (Ventana) on a
BenchMark XT automated stainer (Ventana, Tucson, AZ).
Briefly, the tissue sections were deparaffinized with EZ Prep
at 75°C and 76°C, heat pretreated in Cell Conditioning 1
(CC1) for antigen retrieval at 76°C – 100°C and then incu-
bated with the anti-HER2 primary antibody for 16 min at
37°C after inactivation of the endogenous peroxidase using
UV-inhibitor for 4 min at 37°C. The slides were incubated
with a secondary antibody followed by the application of
HRP Universal Multimer for 8 min. Antibodies were de-
tected using chromogen (for 38 min). Before mounting,
slides were counterstained with hematoxylin II for 4 min
and bluing reagent for 4 min. To support the validity of
staining and identify experimental artefacts, a positive
control was included in each run.
Silver in situ hybridization
Dual colour SISH was performed according to the
INFORM HER2 Dual ISH DNAProbe cocktail and ultra-
VIEW SISH DNP Detection Kit/ultraVIEW RED ISH
DIG Detection Kit for HER2 and Chr 17 quantitation and
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2,4-dinitrophenol (DNP) and digoxigenin (DIG). The tissue
slides were deparaffinized with EZ Prep at 65°C-76°C and
heat pretreated with EZ Prep-diluted Cell Conditioner 2
(CC2) at 90°C followed by protease digestion with ISH
Protease 3 for 16 min at 37°C. The genomic DNA tissue
sections and the nick-translated HER2 and Chr 17 probes
were co-denatured by heat treatment for 20 min at 80°C
followed by a hybridization step for 6 h at 44°C. The HER2
signals were detected using rabbit anti-DNP antibody for
20 min at 37°C and incubated with a HRP-conjugated goat
anti-rabbit antibody for 16 min at 37°C after three 8 min
stringency washes. The signal was detected as silver de-
posits with silver acetate, hydroquinone and hydrogen per-
oxide. For Chr 17 detection, the slides were incubated with
mouse anti-DIG antibody for 20 min at 37°C and with an
AP-conjugated goat anti-mouse antibody for 24 min at
37°C. The Chr 17 signal was developed as red dot staining
with fast red and naphthol phosphate. The slides were
finally counterstained with hematoxylin II and bluing re-
agent before mounting.
Gene/protein
Gene/protein platform combining IHC and SISH on one
slide. To support the validity of staining and identify
experimental artefacts, a positive control was included in
each run.For HER2 protein staining and for HER2/Chr 17
hybridization, the iVIEW DAB Detection Kit and ul-
traVIEW Detection Kits were used. The samples were
stained under several of assay conditions to implement an
optimum protocol needed to achieve IHC/SISH staining
results comparable to those of individual IHC and SISH
testing. The optimization was performed in the laboratory
of Ventana (Roche) and in part in own work. Optimal
results were achieved by performing the IHC procedure
before the SISH procedure.
Samples were deparaffinized with EZ Prep at 72°C in
6 cycles. For HER2 protein staining, the tissue sections
were heat pretreated in CC1 for antigen retrieval at 95°C
and then incubated with the anti-HER2 primary antibody
at 37°C for 48 min after inactivation of the endogenous
peroxidase using UV-inhibitor for 4 min at 37°C. The
slides were incubated with a biotinylated secondary anti-
body followed by the application of HRP-conjugated
streptavidin for 8 min. A copper enhanced DAB reaction
was used to visualize the protein. For HER2 gene and
CHR 17 staining, samples were heat pretreated with EZ
Prep-diluted CC2 at 90°C for four cycles followed by pro-
tease digestion with ISH Protease 2 for 12 min at 37°C.
The probes were denatured for 4 min at 80°C and hybri-
dized for 6 h at 44°C using a cocktail of DNP- and DIG-
labeled probes. HybClear solution was added to block the
interaction between the DNP and the DAB deposit during
hybridization. The gene signals were detected using rabbitanti-DNP antibody for 16 min at 37°C and incubated with
a HRP-conjugated goat anti-rabbit antibody for 16 min at
37°C after four 8 min stringency washes. The signal was
developed by the silver deposit with silver acetate, hydro-
quinone and hydrogen peroxide. For Chr 17 detection, the
slides were incubated with mouse anti-DIG antibody for
16 min at 37°C and with an AP-conjugated goat anti-
mouse antibody for 24 min at 37°C. The Chr 17 signal
was developed as red dot staining with fast red and naph-
thol phosphate. Before mounting, slides were counter-
stained with hematoxylin II for 8 min and bluing reagent
for 4 min.
Pathology review
The samples were independently interpreted by a pa-
thologist (AB) and a biologist trained in gastric cancer
histology (DW). The observers received the samples ran-
domly, i.e. SISH, IHC, and combined method were not
evaluated in association with each other, but separately
for each patient. Consensus of both reviewers was found
after each evaluation. Because discordant results bet-
ween both methods may be a result of intra-observer
variability rather than differences in the staining quality,
discordant cases were reevaluated by a third observer
who was blinded to the results of the first evaluation,
but evaluated the discordant cases (methods) in associa-
tion with each other. Finally, consensus was established
between the third observer and the primary observers.
The IHC results were interpreted using the scoring
scheme proposed for gastric cancer by Hofmann et al.
[17] and Rüschoff et al. [18]: 0, no reactivity or membran-
ous reactivity in < 10% of tumor cells; 1+, faint/barely per-
ceptible membranous reactivity in > 10% of tumor cells;
2+, weak to moderate complete, lateral or basolateral mem-
branous reactivity in > 10% of tumor cells; and 3+, strong
complete, lateral or basolateral membranous reactivity in ≥
10% of tumor cells.
In SISH results, the total numbers of HER2 and chro-
mosome 17 signals were counted in at least 20 tumor cell
nuclei in two different areas. The HER2/Chr 17 ratios
were interpreted in accordance with the ToGA FISH sco-
ring scheme for HER2 testing in gastric and gastroesopha-
geal junction (GEJ) cancer as follows: < 2.0, HER2 gene
not amplified; ≥ 2.0, HER2 gene amplified [17]. An average
count of six or more was regarded as amplified.
Statistical analysis
The analysis was explorative with no predefined hypoth-
esis or sample size calculations. The number of 100 pa-
tients was considered sufficient to perform the proposed
statistical tests. Correlations between IHC/SISH and gene/
protein were estimated using Cohen´s kappa coefficient
(к). The kappa value interpretation by Altmann [19] was
used: к > 0.81, very good agreement; 0.61-0.80, good





(IHC 3+ or SISH +)
single n (%)
Positivity*
(IHC 3+ or SISH +)
combi n (%)
Sex
Female 27 (28.1) 2 (7.4) 1 (3.7)
Male 65 (67.7) 11 (16.9) 11 (16.9)
Unknown 4 (4.2) 3 (75.0) 3 (75.0)
Age 18-94 yrs
(Median 69)
≥ 65 68 (70.8) 12 (17.6) 11 (16.2)





48 (50.0) 5 (10.4) 4 (8.3)
GEJ 44 (45.8) 8 (18.2) 8 (18.2)
Not specified 4 (4.2) 3 (75.0) 3 (75.0)
Lauren
classification
Diffuse 27 (28.1) 3 (11.1) 2 (7.4)
Mixed 4 (4.2) 1 (25.0) 1 (25.0)
Intestinal 65 (67.7) 12 (18.5) 12 (18.5)
Biopsy/
resection
Biopsy 68 (70.8) 10 (14.7) 9 (13.2)
Resection 28 (29.2) 6 (21.4) 6 (21.4)
T stage (n=28)
T 1 4 (14.3) 0 0
T 2 8 (28.6) 2 (25.0) 2 (25.0)
T 3 14 (50.0) 4 (28.6) 4 (28.6)
T 4 2 (7.1) 0 0
N stage (n=28)
N + 24 (85.7) 5 (20.8) 5 (28.8)
N - 4 (14.3) 1 (25.0) 1 (25.0)
M stage (n=28)
M + 5 (17.9) 1 (20.0) 1 (20.0)
M - 18 (64.3) 3 (16.7) 3 (16.7)
Mx 5 (17.9) 2 (40.0) 2 (40.0)
Grading
G2 38 (39.6) 6 (15.8) 6 (15.8)
G2-3 10 (10.4) 2 (20.0) 2 (20.0)
G3 48 (50.0) 8 (16.7) 7 (14.6)
Abbreviations: IHC immunohistochemistry, SISH silver in situ hybridization
T primary tumor, N lymph nodes, M metastases *defined as IHC 3+ or
SISH ≥2.0.
P=1 for all comparisons between IHC/SISH and gene/protein methods (Fisher´s
Exact Test).
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Ninety six of the 100 patient cases were assessable. One
case was excluded because of the absence of tumor cells
and three cases for poor signals in the single SISH
staining.
The majority of patients were male (67.7%) and ≥ 65 years
old (70.8%) (Table 1). The cohort consists of patients with
adenocarcinoma of middle to distal stomach (50.0%) or
GEJ (45.8%) with more cases of Lauren`s intestinal (67.7%)
than diffuse tumors (28.1%). The grading of the majority of
samples was G3 (50.0%) followed by G2 (39.6%) and tu-
mors classified as G2-3 (10.4%). 85.7% of resected patients
(n = 28) showed lymph node metastasis (N stage) and
64.3% showed no distant metastases (M stage). In the half
of the resected patients, T3 tumor stage was observed,
followed by T2 in 28.6%, T1 in 14.3% and T4 stage in 7.1%
of patients.
In Table 1 the HER2 positivity by subgroups is also
presented. No significant difference was noted in HER2
positivity when compared to subgroups and different
methods.
Staining results for HER2 protein expression and gene
amplification (single staining methods)
Protein expression scores by IHC were 0 and 1 + in
70.8% and 10.4% of patients (Table 2). 2.9% of score 0
and 10.0% of score 1 + cases were amplified. In 9.4% of
cases, a moderate expression (score 2 +) with 44.4%
amplified cases was detected. 9.4% of the stained sam-
ples showed a strong expression (score 3 +) with 77.8%
amplified cases. Figure 1 demonstrates representative re-
sults from single staining.
Gene/protein (combined staining method)
Protein expression scores by gene/protein method were
0, 1+, 2+, and 3+ in 70.8%, 11.5%, 7.3% and 10.4%
(Table 2). There were 2.9% / 9.1% amplified cases in sam-
ples with score 0 / 1+. 28.6% amplified cases showed a
moderate staining (score 2+). Samples with high expres-
sion (3+) showed in 90.9% gene amplification. Examples
of gene/protein staining are demonstrated in Figure 1.
Evaluation of Concordant and discordant cases
The assessment of IHC staining in the conventional sin-
gle and the gene/protein method did not always reveal
congruent results; agreements of both methods were
also listed in Table 3 There were very good concor-
dances in results of amplified cases (agreement 100.0%;
Table 2 Staining results for HER2 protein expression and
gene amplification
Single method Combined method
IHC Score IHC (n=96) SISH ≥ 2.0 IHC (n=96) SISH ≥ 2.0
n (%) n (%) n (%) n (%)
0 68 (70.8) 2 (2.9) 68 (70.8) 2 (2.9)
1+ 10 (10.4) 1 (10.0) 11 (11.5) 1 (9.1)
2+ 9 (9.4) 4 (44.4) 7 (7.3) 2 (28.6)
3+ 9 (9.4) 7 (77.8) 10 (10.4) 9 (90.9)
Abbreviations: IHC immunohistochemistry, SISH silver in situ hybridization.
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score 1+ (98.96%; κ = 0.947) and score 3+ tumor samples
(96.88%; κ = 0.825) in both methods. Cases with score
2+ showed less concordance, although still good (95.83%;
κ = 0.728). Concordance between the overall HER2 posi-
tivity (defined as IHC 3+ or SISH+) in standard or novel
method was very good (98.69%; κ = 0.963; 17.7% vs.
16.7%).
There were twelve discrepant cases before re-analyzing
by a third observer (data not shown). After re-evaluation
by a third observer, discrepant results remained in four
tumor samples. The reason for the eight discrepant cases
in the interim analysis was found to be intra-observer
variability. Results of the final discordant results are
shown in Table 4.
Discussion
The aim of this study was to evaluate the feasibility of
new gene/protein platform in comparison to the single
staining methods in gastric adenocarcinomas and carci-
nomas of the esophagogastric junction.
Of the evaluable samples 28.1% showed a diffuse, 4.2% a
mixed and 67.7% an intestinal histological type. The ma-
jority of patients were ≥65 years old (70.8%) and male
(67.7%). The rate of adenocarcinoma of GEJ or middle to
distal stomach was similar (45.8% vs. 50.0%). In the stan-
dard method, 17.7% of patients were HER2 positive. The
majority of HER2-positive tumors were of intestinal hist-
ology and were localized in the GE junction, this corre-
lates well with data of literature [20,21]. Overall, based on
patient and tumor characteristics as well as HER2 posi-
tivity, the evaluated group is a representative collective.
Although considerable experience for HER2 analysis by
IHC and ISH for breast cancer is available, it is not certain
whether they can be directly transferred to carcinomas of
the gastrointestinal tract. The expression of HER2 protein,
unlike in carcinoma of the breast, is heterogeneous and
often focally pronounced. Fox et al. [12]. determined the
HER2 status in 100 tissue samples diagnosed with ad-
vanced stomach cancer or cancer of the esophagogastric
junction in different laboratories to test their matches. For
this, IHC and CISH (chromogenic in situ hybridization)or SISH were applied. There was a good agreement bet-
ween the different laboratories regarding CISH or SISH,
but moderate concordance for all IHC scores was ob-
served. Based on the results of the investigation, the
author's opinion was that a determination of HER2 status
based on IHC, followed by ISH (European standard) is not
an optimal evaluation strategy and recommended per-
forming both staining methods [12]. Another study [22]
tested the HER2 amplification and expression in 148 pa-
tients with advanced gastric carcinoma by IHC and FISH/
SISH. Positive HER2 cases were detected in only 10% of
the IHC compared with 18% to 22% in the in situ
hybridization. Not only because it was easier to reproduce,
the author proposed the in situ hybridization technique as
the better approach for determining the HER2 positivity
[22]. However, based on the TOGA trial [8], patients with
ISH positive but IHC negative or weekly (1+) positive tu-
mors did not benefit from trastuzumab. Therefore, the use
of FISH or SISH as the primary and only method is not
recommended in Europe and IHC is still considered as
the primary evaluation method in many countries.
To the best of our knowledge, however, there are no
studies that directly compare results of both immu-
nohistochemistry (IHC) and silver in situ hybridization
(SISH) when each is used separately with the results of
using them in combination on a single section in gastric
carcinomas. To visualize RNA and DNA targets in situ,
there are different ways of labeling probes using fluo-
rescence, chromogenic or silver detection. All previous
studies with settings comparable to our analysis used
chromogenic or fluorescence in situ hybridization (CISH
or FISH). Downs-Kelly et al. [14] combined standard IHC
with a deposition of metallic silver by EnzMetTM on a
tissue microarray (TMA) of breast carcinomas and
compared the results of IHC and fluorescence in situ
hybridization (FISH) when performed alone. In another
study, the authors has indeed used the combination of
IHC and silver in situ hybridization (SISH) in TMA of
breast and gastric cancer samples, but compared the re-
sults of those obtained by IHC and fluorescence in situ
hybridization (FISH) as single staining [16]. Reisenbichler
et al. [15] reported the results of the comparison of IHC
and chromogenic in situ hybridization (CISH) as single
stainings with the dual assay IHC/CISH. The simulta-
neous evaluation of protein and gene combinations on a
single slide offered a highly reproducible and very robust
method with good concordances.
To test the validity of the new gene/protein staining
compared with the standardized IHC and SISH, the con-
cordances were calculated based on the kappa coeffi-
cient. According to the ASCO/CAP guidelines for breast
cancer, a new test should show more than 95% concor-
dance with a validated reference assay [23]. In our study,
the new method showed concordances above 95% in
Figure 1 Representative results of the different staining methods. Intestinal tumor (hematoxylin and eosin (H&E), A.1, 20x) with IHC 3+
(immunohistochemistry (IHC), A.2, 20x; gene/protein, A.4, 20x) and amplification (silver in situ hybridization (SISH), A.3, 40x; gene/protein, A.4, 20x).
IHC score 0 (IHC, B.2, 20x; gene/protein, B.4, 40x), intestinal type (H&E, B.1, 20x) and amplification (SISH, B.3, 40x; gene/protein, B.4, 40x).
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dances in results of gene amplification as well as score 0
(each with 100% agreement), score 1+ (98.96% agree-
ment) and score 3+ tumor samples (96.88% agreement).Cases with score 2+ showed less concordant results,
although still good (95.83% agreement). Difficulties in
cases with moderate expression in the assessment and
classification are known in the literature. Tafe et al. [24].
Table 3 Concordances between single methods and combined gene/protein methods
Single vs. combination Concordance Kappa-Coefficient к Agreement Altmann [15]
SISH amplified 100 % 1 Very good
IHC score 0 100 % 1 Very good
IHC score 1+ 98.96% 0.947 Very good
IHC score 2+ 95.83% 0.728 Good
IHC score 3+ 96.88% 0.825 Very good
Abbreviations: IHC immunohistochemistry, SISH silver in situ hybridization.
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score in the evaluation of the IHC due to lack in the reli-
able separation of cases with a HER2 score of 1 + or 2 +.
These categories might be limited by subjectivity and
poor reproducibility. The phenomenon that discordant
results are observed in patients with low HER2 expres-
sion, who sometimes still have HER2 gene amplification,
has been reported in esophageal cancer [24-26]. The
most probable reason for this discordance is intra-tumor
heterogeneity of HER2 status in gastric or GEJ cancer
[17,27,28]. In our study, discordant IHC results were ob-
served in four patients, but these have led to a clinically
relevant difference in HER2 positivity in one patient only
(patient #1057). The patient had diffuse type gastric can-
cer. The evaluation of diffuse tumors seems to be more
difficult than intestinal type tumors [29,30]. According
to Rüschoff et al. [18]. only 5% of these tumors show
HER2 positivity; signet ring cell carcinomas are negative.
HER2 amplification is extremely rare in diffuse gastric
carcinoma which is associated with abnormal E-cadherin
expression [13,31-33].
The SISH is a relatively new method for the detection
of the amplification of the HER2 gene. Numerous stu-
dies confirmed a high concordance with other in situ
hybridization methods like CISH and FISH [34]. Com-
pared to the IHC, ISH shows a higher sensitivity and
specificity and a higher reproducibility. This statement
can be confirmed by comparing the concordance of
amplified cases in our methods. Results revealed a very
good agreement between both methods (100.0%; к = 1).Table 4 Detailed evaluation of discordant results between me
Single meth





Abbreviations: IHC immunohistochemistry, SISH silver in situ hybridization.Furthermore, the ISH is less sensitive than IHC due to a
relative stability of DNA compared to differences in tis-
sue fixation and processing.
We are currently working on an expanded study eva-
luating whether this new method is associated with a re-
duction of inter-observer variability in the determination
of HER2 status in gastric cancer. This study also in-
cludes a component looking at the time needed to report
final results. The results will be submitted to the journal
as letter or an original report, as soon as they are
available.
Conclusions
In this study, we have clearly shown that using the com-
bined method to perform HER2 protein expression and
gene amplification on a single slide can produce results
similar to those using each method individually in a con-
trolled study implementing three independent observers.
We believe that the new gene/protein staining provides
a good alternative to the conventional standard method
IHC and ISH and may theoretically reduce the possibil-
ity that a gastric cancer patient will receive an incorrect
HER2 status assessment and thus an incorrect treat-
ment. This may apply especially for cases that are diffi-
cult to interpret because they have a score of 1+ or 2+,
as well as in heterogeneous and diffuse cases. Moreover,
the direct combination of the two staining methods can
save precious patient material, since only a single tissue
section is required. This has become an important tis-
sue, as numerous biomarkers are currently under clinicalthods
ods Combined method
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Further, the staining can also be a time saving. However,
it is important to note that these potential advantages
are still theoretical and have to be proven in a future
study.
Abbreviations
IHC: Immunohistochemistry; SISH: Silver in situ hybridization; IHC/SISH: Single
methods; gene/protein: Both methods on one slide combined;
EGFR: Epidermal growth factor receptor; mTOR: Mammalian target of
rapamycin; FFPE: Formalin-fixed paraffin-embedded; H&E: Hematoxylin and
eosin; CC1: Cell Conditioning 1; DNP: 2,4-dinitrophenol; DIG: Digoxigenin;
CC2: Cell Conditioning 2; GEJ: Gastroesophageal junction; CISH: Chromogenic
in situ hybridization; FISH: Fluorescence in situ hybridization; TMA: Tissue
microarray.
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